University of California

Genentech, Inc.

Onyx Pharmaceuticals, Inc.

Foundation Medicine, Inc.

David Hugh Stokoe

David Jablons

Biao He

Naoaki Fujii

Irwin D Kuntz

Liang You

Zhidong Xu

R Kiplin Guy

Kathleen P Novak

Jose Haresco

James M Lee

Len Stephens

Christiaan Nicolaas Klijn

Philip Thomas Hawkins

Ryan J Hartmaier

Juliann Chmielecki

Leonard David Goldstein

Florian Gnad

Robert Gentleman

James Lee

The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.

Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene

Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula  The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.

Small molecule inhibition of a PDZ-domain interaction

Compositions and methods are described that are useful to assay for compouds that affect PKB kinase activity which have medical applications for the diagnosis and treatment of disease.

Compositions and methods for identifying PKB kinase inhibitors

Growing community of inventors

San Francisco, CA, United States of America

David Hugh Stokoe